Home
About
Overview
Sharing Data
ORCID
Help
History (66)
Lack of Phenotypic Differences by Cardiovascular Magnetic Resonance Imaging in MYH7 (?-Myosin Heavy Chain)- Versus MYBPC3 (Myosin-Binding Protein C)-Related Hypertrophic Cardiomyopathy.
DiVito, Cheryl
Leucine-Responsive Regulatory Protein
Sedentary Lifestyle
FGFR inhibitors in urothelial cancer: Contextualizing THOR within the new treatment landscape.
See All 66 Pages
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
FGFR inhibitors in urothelial cancer: Contextualizing THOR within the new treatment landscape.
Mittal K, Joshi M. FGFR inhibitors in urothelial cancer: Contextualizing THOR within the new treatment landscape. Med. 2024 Mar 08; 5(3):176-178.
View in:
PubMed
subject areas
Carcinoma, Transitional Cell
Humans
Immunotherapy
Molecular Diagnostic Techniques
Molecular Targeted Therapy
Urinary Bladder Neoplasms
authors with profiles
Kriti Mittal MD